LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
=== Regulation === The level of regulation includes Schedule IV non-narcotic (depressant) (ACSCN 2285) in the United States under the Controlled Substances Act 1970—but along with a few other barbiturates and at least one benzodiazepine, and codeine, dionine, or dihydrocodeine at low concentrations, it also has exempt prescription and had at least one exempt OTC combination drug now more tightly regulated for its ephedrine content. The phenobarbitone/phenobarbital exists in subtherapeutic doses which add up to an effective dose to counter the overstimulation and possible seizures from a deliberate overdose in ephedrine tablets for asthma, which are now regulated at the federal and state level as: a restricted OTC medicine and/or watched precursor, uncontrolled but watched/restricted prescription drug & watched precursor, a Schedule II, III, IV, or V prescription-only controlled substance & watched precursor, or a Schedule V (which also has possible regulations at the county/parish, town, city, or district as well aside from the fact that the pharmacist can also choose not to sell it, and photo ID and signing a register is required) exempt Non-Narcotic restricted/watched OTC medicine.
== Toxicity == Studies carried out on the toxicity of convulxin show that symptoms are a function of the dose. The effects of the toxin stand out through the sudden and brief duration of the symptoms after exposure. In mice, low doses (5 μg/animal) administered intravenously (I.V) elicited tachypnea, followed by apnea, within 20 seconds. The ED50 for brief duration apnea was determined to be 180 μg/kg. Higher doses (10 μg/animal) evoked intense convulsive crisis, and usually ended with the death of the animal. LD50 was determined to be 524 μg/kg. Intraperitoneal (I.P.) administration of up to 200 μg/animal proved to be ineffective. In cats, I.V. injections of 100 μg/kg showed respiratory disturbances, miosis, salivation, abdominal cramps, nystagmus, loss of equilibrium, convulsions and sometimes a brief phase of hypotonia. The ED50 dose for convulsions is 80 μg/kg. The majority of animals recovered within 30 minutes. In dogs, the effect of convulxin showed two stages. After I.V. injection of 100-125 μg/kg they became excited, barked and exhibited loss of equilibrium, respiratory disturbances, nystagmus, urination, defecation and vomiting. After recovery, two out of five animals had intermittent crisis of clonic convulsions that appeared after 24 hours and lasted until their death. The other three dogs showed periods of vivid agitation alternating with torpor. While the lethal dose in humans is not yet known, what has been discovered is that the level of toxic effects depends on the origin of the snake. As for a cure, so far a polyvalent snake antivenom is being used.
=== Cancer and Infectious Diseases === A significant area of LMRT's work involves developing nanomaterials as tools for biological studies and as multifunctional agents for cancer therapies. This includes designing nanoparticles and nanoporous materials that can home in on tumors, signal cellular changes, enhance imaging, or deliver therapeutic components. Early work in 2002, with Erkki Ruoslahti, involved developing phage-derived peptide-targeted nanomaterials for in vivo tumor targeting. More recently, Bhatia, in collaboration with Erkki Ruoslahti and Michael Sailor, has explored engineering beneficial probiotics to detect or treat cancer cells. For over a decade, LMRT has pioneered new technologies in activity-based diagnostics. This includes designing nanosensors with biological molecules, such as peptide barcodes, that can signal the presence of diseases like cancer when interacting with aberrantly active enzymes (proteases) in diseased tissue. These specialized nanoparticles allow for detection via simple tests on urine similar to an at-home pregnancy test, breath, or blood samples. This platform has expanded to detect 12 diseases, including 6 cancer types. Nanosensors can be administered via inhalation, intramuscular injection, and even ingested in the form of probiotic bacteria. The LMRT is also exploring breath-based diagnostics for rapid results and has developed diagnostic tools that use DNA barcodes and CRISPR technology, making cancer diagnostics more affordable and accessible for low- and middle-resource settings.
=== Other endurance sports === In triathlon, 2004 Hawaii Ironman winner Nina Kraft, was disqualified for a positive test to EPO. She remains the only Hawaii Ironman winner to be disqualified for doping offences. Sports lawyer Michelle Gallen has said that the pursuit of doping athletes has turned into a modern-day witch-hunt.
Afterwards, Xi gave a speech, stating he was glad to visit the "beautiful" United States, thanked Trump for the hospitality and said "On behalf of the 1.4 billion and more Chinese people, I wish to begin by extending sincere greetings to the American people and the warm congratulations on the 250th anniversary of the US independence". He said both countries are great countries with great people, and that he was visiting to continue the friendship and expand co-operation. He added that as two major countries, China and the US show "their historic responsibility of advancing human development and progress". He also said that he is ready to "work with Trump to steer the giant ship of the China-US relationship towards a steady future". Xi said that "China and the US are different... but through candid, in-depth, and continued dialogue, our two countries can understand each other better... and build up mutual trust". He stated he and Trump had "respect" for each other and stayed in touch, and that "We should co-operate with sincerity". He said even though cooperation between the two nations "may not solve every problem in the world", it would be hard to solve major problems without it.
Sources: en.wikipedia.org
The University of North Carolina School of Medicine (UNC School of Medicine, UNC SOM) is the medical school of the University of North Carolina at Chapel Hill. Founded in 1879, it is closely affiliated with UNC Health and UNC Medical Center, and serves as a major center for medical education, clinical care, and biomedical research in North Carolina. The school offers a range of graduate and professional medical programs, including Doctor of Medicine (MD), combined MD/PhD, and combined MD/MPH degree programs, and academic health science programs including physical therapy, physician assistant, and clinical laboratory science.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed EDC is a strong skin sensitizer, showing a response at <0.01 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows EDC poses minimal explosion risks.
Controlled animal and human studies showed that caffeine (energy drinks) in combination with alcohol increased the craving for more alcohol more strongly than alcohol alone. These findings correspond to epidemiological data that people who consume energy drinks generally showed an increased tendency to take alcohol and other substances.
=== Cancer === Bleomycin is mostly used to treat testicular cancer, ovarian cancer, and Hodgkin's disease, and less commonly non-Hodgkin's disease. It can be given intravenously, by intramuscular injection, or under the skin.
β-Methylamino-L-alanine, or BMAA, is a non-proteinogenic amino acid produced by cyanobacteria. BMAA is a neurotoxin. Its potential role in various neurodegenerative disorders is the subject of scientific research.
Sources: en.wikipedia.org
L'Atalante by Jean Vigo (1934) Le Quai des brumes by Marcel Carné (1938) Un homme marche dans la ville by Marcello Pagliero took place in the port and the Saint-François district after the Second World War. Ce qu'ils imaginent by Anne Théron (2004) The city has also hosted the filming of several comedies such as:
De emerges, in retrospect, as a modest self-effacing scientist driven by inner compulsions to grapple with a major scientific problem of the time. His choice of cholera as his field of interest was remarkably appropriate to his setting. To this problem De brought a wonderfully thoughtful approach, together with deep intuition, enabling him to make the long-awaited breakthrough in the field."
== Release and promotion == III was released digitally on November 7, 2012, in the United States, and the CD was released on November 8 in Australia, Canada, and the United States. The album's first two singles, "Plague" and "Wrath of God", were made available for free download on the duo's SoundCloud page on July 25 and September 26, 2012, respectively. The accompanying music video for "Plague" debuted on September 24, 2012, and uses footage from Andrzej Żuławski's 1981 film Possession. "Affection" was released as the album's third single on October 31, 2012. The music video for "Affection" premiered on April 26, 2013, and was filmed on the duo's South American tour. "Violent Youth" premiered on Zane Lowe's BBC Radio 1 show on November 1, 2012. A music video for "Sad Eyes", shot in Berlin and Toronto, was released on January 20, 2013. On July 26, 2012, Crystal Castles announced a North American tour with Health and Kontravoid in support of the album, as well as festivals appearances in Europe and Australia, starting on August 9, 2012, and ending on January 28, 2013. In November 2012, the band performed six dates in the United Kingdom. Additional dates across Europe, Oceania, North America, and South America were announced on October 17, 2012, and January 9, 2013. III is The Last Album to Feature Alice Glass, along with the current Roman numeral pattern
Charnia fossils were originally found in the Charnwood Forest in England, hence named Charnia. These fossils are from marine organisms that lived on the bottom of the ocean floor. The fossils have a fractal body plan and were frond shaped, meaning they resembled broad-leafed plants such as ferns. However they could not have been plants since they resided in the dark depths of the ocean floor. In Charnwood Forest, Charnia was found as an isolated species, however there were many more fossils found on the East Coast of Canada in Mistaken Point in Newfoundland. Charnia was attached to the bottom of the ocean floor, and was strongly current aligned. This is seen because there are disk-like shapes at the bottom of the Charnia fossil, which show where Charnia was tethered, and all the nearby fossils are facing the same direction. These fossils at Mistaken Point were preserved well under volcanic ash and layers of soft mud. It has been determined via radiometric dating of the fossils that Charnia must have lived around 565 million years ago.
== Clinical significance == There are two congenital disorders of the long bones. In a disorder known as rachitis fetalis anularis the ends of the long bones (epiphyses) are enlarged. Another disorder, rachitis fetalis micromelica, is a deficiency in the growth (as a shortness) of the bones. There is a surgical procedure called distraction osteogenesis which is used to lengthen long bones.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.